Agnieszka Brozyna

Agnieszka Brozyna

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2008 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
BDBozenna Dembowska-Baginska
Bozenna Dembowska-Baginska
DPDanuta Perek
Danuta Perek
ABAgnieszka Brozyna
Agnieszka Brozyna
AWAnna Wakulinska
Anna Wakulinska
DODorota Olczak-Kowalczyk
Dorota Olczak-Kowalczyk
KCKrystyna Chrzanowska
Krystyna Chrzanowska

31 May 2012 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
EJElzbieta Jurkiewicz
Elzbieta Jurkiewicz
ABAgnieszka Brozyna
Agnieszka Brozyna
WGWiesława Grajkowska
Wiesława Grajkowska
Monika Bekiesinska-FigatowskaMonika Bekiesinska-Figatowska
Monika Bekiesinska-Figatowska
PDPaweł Daszkiewicz
Paweł Daszkiewicz
MSMalgorzata Syczewska
Malgorzata Syczewska

11 November 2019 in Cancers
Verified
Journal Article
Open access
PDF file
BDBozenna Dembowska-Baginska
Bozenna Dembowska-Baginska
JWJolanta Więckowska
Jolanta Więckowska
ABAgnieszka Brozyna
Agnieszka Brozyna
EŚEwa Święszkowska
Ewa Święszkowska
HIHor Ismail
Hor Ismail
PKPiotr Kaliciński
Piotr Kaliciński
The aim of this study was to evaluate the health status of children cured from hepatoblastoma. Forty-five patients with hepatoblastoma treated between 1996–2014 were assessed. The recorded data included sex, age at diagnosis, disease stage, treatment methods, time since diagnosis, and the evaluation of health status domains which included performance status, growth development, hearing, cardiovascular, skeletal, gastrointestinal, genitourinary, neurological, and hematological function. There were 30 boys and 15 girls. The age at diagnosis ranged from one month to 14 years (median one year). At the time of the health status evaluation, the youngest patient was 5.5 years old and the oldest was 21 years of age (median—10 years). All patients were treated according to the Childhood Liver Tumors Strategy Group—SIOPEL recommendations, though they were not active participants of the studies. The median cumulative dose of cisplatin was 520 mg/m2 and 360 mg/m2 for doxorubicin. Thirty-six patients underwent partial hepatectomy, and nine total hepatectomy and liver transplantation. At a median of nine years from diagnosis, 68% of hepatoblastoma survivors had experienced at least one chronic health condition of any grade. The most frequent late complication was ototoxicity (28.8%), and the most serious were second malignancies (6.6%) and cardiomyopathy (4.4%). Conclusion: Survivors of hepatoblastoma are at risk for long-term complications. They require long-term monitoring for late effects.

1 January 2018 in Journal of Clinical Pediatric Dentistry
Verified
Journal Article
Closed access
DODorota Olczak-Kowalczyk
Dorota Olczak-Kowalczyk
EKEwa Krasuska-Sławińska
Ewa Krasuska-Sławińska
ABAgnieszka Brozyna
Agnieszka Brozyna
ASAnna TURSKA - SZYBKA
Anna TURSKA - SZYBKA
BDBozenna Dembowska-Baginska
Bozenna Dembowska-Baginska
Objective: To assess caries incidence, intensity, and treatment in children and adolescents under/after antineoplastic treatment. Study design: Patients with permanent and mixed dentition were divided into three groups of 60 patients each (5–18 years): CH – under chemotherapy; PCH – after chemotherapy; CG – generally healthy subjects. Caries incidence, intensity (DMFT/dmft, DMFS/dmfs), and mean numbers of teeth/surfaces with white spot lesions–WSL (D1+2/d1+2) were assessed following the ICDAS-II criteria. Statistical analysis: Mann-Whitney U test, significance at p≤0.05). Results: Caries incidence was significantly higher in PCH and CH (88.33% and 90%) than in CG (66.66%). Caries intensity was higher in both mixed and permanent dentition in patients under and after chemotherapy. The DMFS/DMFT correlation was the highest in PCH. Treatment indexes for primary and permanent teeth treatment were significantly lower in PCH and CH than CG. Conclusion: Antineoplastic chemotherapy is associated with caries development and its high incidence during/after treatment. As dental hygiene was poor in patients under and after antineoplastic treatment, dental checkups need to be more frequent and thorough.

1 January 2016 in Contemporary Oncology
Verified
Journal Article
Open access
EKEwa Krasuska-Sławińska
Ewa Krasuska-Sławińska
ABAgnieszka Brozyna
Agnieszka Brozyna
BDBozenna Dembowska-Baginska
Bozenna Dembowska-Baginska
DODorota Olczak-Kowalczyk
Dorota Olczak-Kowalczyk
Aim of the study : Chemotherapeutic treatment in children and adolescents carries a risk of congenital tooth disorders and dentinoma. Study objective is to assess the correlation between tooth abnormalities, early complications of multidrug chemotherapy, and chemotherapeutics used in different...

1 June 2021 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
IMIwona Malinowska
Iwona Malinowska
MRMichał Romiszewski
Michał Romiszewski
KSKatarzyna Smalisz
Katarzyna Smalisz
ASAnna Stelmaszczyk-Emmel
Anna Stelmaszczyk-Emmel
BABarbara Nasilowska - Adamska
Barbara Nasilowska - Adamska
BDBozenna Dembowska-Baginska
Bozenna Dembowska-Baginska